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Randomized Trial of a Shared Decision-Making
Intervention Consisting of Trade-Offs and
Individualized Treatment Information for BRCA1/2
Mutation Carriers
M.S. van Roosmalen, P.F.M. Stalmeier, L.C.G. Verhoef, J.E.H.M. Hoekstra-Weebers, J.C. Oosterwijk,
N. Hoogerbrugge, U. Moog, and W.A.J. van Daal
A B S T R A C T
Purpose
To evaluate a shared decision-making intervention (SDMI) for BRCA1/2 mutation carriers who have to
make a choice between screening and prophylactic surgery for breasts and/or ovaries.
Patients and Methods
The SDMI consisted of two value assessment sessions, using the time trade-off method, followed by
individualized treatment information based on (quality-adjusted) life expectancy. After the baseline
assessment (2 weeks after a positive DNA test result), women were randomly assigned to the SDMI
group (n  44), receiving the SDMI 2 months after the test result, or to the control group (n  44). The
short- and long-term effects, 3 and 9 months after the test result, were assessed using questionnaires.
Data were collected on well-being, treatment choice, and decision-related outcomes.
Results
In the short term, the SDMI had no effect. In the long term, with respect to well-being, patients in the
SDMI group had less intrusive thoughts (P  .05) and better general health (P  .01) and tended to be
less depressed (P  .07). With respect to decision-related outcomes for the breasts, the SDMI
group held stronger preferences (P  .02) and agreed more strongly to having weighed the pros and
cons (P  .01). No effect was found on treatment choice. In the long term, interaction effects between
the SDMI and cancer history were found. The SDMI showed an overall beneficial effect for unaffected
women, whereas affected women tended to experience detrimental effects.
Conclusion
We conclude that the SDMI improved decision making in unaffected BRCA1/2 mutation carriers.
Supporting decision making in a systematic way using trade-offs is beneficial for these women.
J Clin Oncol 22:3293-3301. © 2004 by American Society of Clinical Oncology
INTRODUCTION
The identification of the BRCA1 and BRCA2
genes has created the possibility to test for
inherited susceptibility of breast and ovarian
cancer.1,2 BRCA1/2 mutation carriers, unaf-
fected with cancer, have a high lifetime risk
of developing breast (56% to 85%) and
ovarian cancer (16% to 63%).3-5 BRCA1/2
mutation carriers already affected with
breast cancer have a high risk of developing a
second breast cancer (up to 63%).6 In the
Netherlands, options available to BRCA1/2
mutation carriers are intensive screening or
prophylactic surgery, including prophylac-
tic mastectomy and prophylactic oophorec-
tomy. Screening of breasts and ovaries is
associated with the risk of cancer that may
be detected too late for effective treatment.
Although prophylactic surgery gives a sig-
nificant reduction in cancer risk and can also
be successful in reducing cancer worries,7 it
may cause adverse psychologic and social
outcomes in some women.8 Thus BRCA1/2
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mutation carriers are confronted with a difficult dilemma in
which a trade-off between duration and quality of life plays
a crucial role.
There is a movement toward greater patient involve-
ment in treatment decisions, which is often referred to as
shared decision making. Shared decision making recognizes
that there are complex trade-offs in the treatment choice.
Shared decision making also addresses the ethical need to
fully inform patients about the risks and benefits of the treat-
ment options, as well as the need to ensure that patients’ values
play a prominent role. For medical decisions with more than
one reasonable option, patient participation in decision mak-
ing is necessary to make treatment decisions, taking patient
values into account. The actual tools to help with shared deci-
sion making are called decision aids (DAs).
DAs can be used as an adjunct to standard counseling
to prepare patients for decision making. According to the
Cochrane definition, DAs are interventions designed to
help people make a specific and deliberative choice among
options by providing information about the options and
outcomes, relevant to a person’s health status.9 A variety of
formats can be used. The most common formats are bro-
chures, audio- and videotapes, decision boards, and inter-
active computer programs.9 Some DAs include tasks to
clarify individual values to promote better congruence be-
tween the individual values and the treatment choice; how-
ever, this is an understudied area.10 A systematic review of
randomized trials has shown that DAs improve patient
knowledge, comfort, and participation in decision making.9
It is not clear which type of DA is most powerful, although
more comprehensive programs seem to have larger effects.9
The goal of our study was to evaluate the use of DAs in
women testing for a BRCA1/2 mutation. DAs may facilitate
decision making for these women by helping them to arrive
at an informed, preference-based treatment choice. We
conducted a shared decision-making study that included
two different interventions. In the first part of the study, we
evaluated the effects of an informative DA and its timing
before or after testing positive for a BRCA1/2 mutation.11
This DA consisted of a brochure and video providing in-
formation on screening and prophylactic surgery. In the
second part of the study, reported here, we evaluated the
effects of a shared decision-making intervention (SDMI) in
BRCA1/2 mutation carriers on well-being, treatment choice,
and decision-related outcomes. The SDMI consisted of two
value assessment sessions, by use of the time trade-off (TTO)
method12 followed by individualized treatment information
based on life expectancy (LE) and quality-adjusted life expect-
ancy (QALE) derived from decision analysis.13 Decision anal-
ysis offers a method to combine individual values regarding
treatment outcomes with individual risk profiles. For the treat-
ment choice for BRCA1/2 mutation carriers, individual values
were shown to be important.13-17 Although such interventions
have been described previously,18-23 they have mainly concen-
trated on the impact of patient preferences on treatment
choice, whereas in our study we focus on a much broader
range of outcomes.
PATIENTS AND METHODS
Study Population
The study was implemented in the Family Cancer Clinics of
the University Hospitals of Nijmegen (beginning March 1999),
Groningen (beginning June 1999), and Maastricht (beginning
January 2000). Study entry closed in November 2001. Both
women affected and unaffected with breast/ovarian cancer who
had chosen to undergo DNA testing were eligible. Women were
excluded if they were unable to give informed consent, had insuf-
ficient knowledge of the Dutch language, were diagnosed with
distant metastases, had undergone both bilateral mastectomy and
oophorectomy, or had been treated with chemotherapy, radio-
therapy, or surgery for breast/ovarian cancer less than 1 month
before blood sampling. Women were ongoing in the study only
when a deleterious BRCA1/2 mutation was found.
SDMI
The SDMI was provided by a trained research assistant and
consisted of three sessions with an interval of 1 to 2 weeks. In the
first session, individual values for the treatment options (screening
and prophylactic surgery) were assessed in a face-to-face interview
by use of the TTO method.12 In the second session, the TTO
interview was repeated by telephone. The questions asked in the
face-to-face and telephone interview were identical. In a previous
study, in a comparable study sample, we judged the TTO method
to be feasible, reliable, and valid24 and strongly predictive of treat-
ment intentions.25 Many women commented that the trade-off
task led to a thoughtful evaluation of the health outcomes and
considered the trade-off to be relevant.24 The TTO interview is
described in detail in the next paragraph. Decision analysis was
used to arrive at individualized treatment information based on
LE and QALE.13 QALE is calculated by multiplying the TTO value
by the LE: TTO values were used as a weighing factor to adjust the
remaining life years for the quality of life that will be experienced.
In the third session, individualized treatment information was
shared with the women using two bar charts, one for LE and one
for QALE. The bar charts presented the treatment options relative
to each other (see Appendix). Absolute LE and QALE information
was not given because we also included women with cancer, who
were not always fully aware of their prognosis. However, we did
present the absolute gains and losses in LE and QALE of prophy-
lactic surgery compared with screening. To avoid the derivation of
prognosis, the bar charts were not to be taken home.
TTO Interview
The TTO interview started with an introduction, an example,
and a flow-chart in which the women had to answer a series of
questions.26 The value assessment started as follows: the health
states following the treatment options were described in bullet-
point format on laminated cards, and the women were asked to
rank them in order of preference. Values for each health state were
then elicited with a flow-chart using the TTO method.26 Women
were asked to choose between two certain options. Option 1 is to
continue living with prophylactic surgery for a fixed time t (such as
the rest of life until age 80 years). Option 2 is to continue living
with screening for a time x less than t. Using forced choices, we
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found how many years (x) in the health state screening was equiv-
alent to a defined time (t) in the poorer health state prophylactic
surgery. Time was used as the unit of comparison. By comparing the
two times x and t, the value for each health state could be calculated.
The TTO value for prophylactic surgery was calculated as (x/t). For
example, a respondent who was indifferent between living with pro-
phylactic surgery for 40 more years and living with screening for 20
more years was assigned a TTO value of 0.5 (20/40) for prophylactic
surgery. We used the ping-pong technique to identify the indifference
point. This involved alternating between long- and short-term time
periods x for screening. To mitigate any ordering effects, the presen-
tation of health states was randomly allocated before the interview.
Study Procedure
Data described here were collected during a longitudinal ran-
domized study (T1 to T5) evaluating an informative DA and its
timing (T1 to T3)11 and the SDMI (T3 to T5; Fig 1). The study was
approved by the hospital ethics boards. Clinical geneticists or genetic
counselors briefly introduced the study after a blood sample for
BRCA1/2 testing was obtained. A research assistant subsequently con-
tacted these women by phone to confirm eligibility and to discuss the
study. Women who gave verbal consent were enrolled and were
mailed an informative letter describing the study and a consent form.
In the first part of the study (T1 to T3; Fig 1),11 not reported
here, women were randomly assigned to the DA group (the DA
Fig 1. Study design: T1 to T3, first part of
the study (not reported here); T3 to T5,
second part of the study (reported here). X,
usual care; DA, (informative) decision aid;
SDMI, shared decision-making intervention.
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was provided 2 weeks after blood sampling) or to the control
group (receiving usual care). The DA was added to usual care and
was to be viewed at home. It consisted of a brochure and video
providing information on screening and prophylactic surgery, and
the physical, emotional, and social consequences. At T2 (4 weeks
after blood sampling), the DA group was compared with the
control group. After testing positive, the control group too re-
ceived the DA. At T3, 2 weeks after disclosure of a positive test
result, we compared the impact of timing (before of after a positive
test result) of the DA. The DA had positive effects on information-
related outcomes only (subjective knowledge, satisfaction with
information, and risk perception); timing of the DA had no ef-
fect.11 Women were ongoing in the study only if a deleterious
BRCA1/2 mutation was found.
In the second part of the study (T3 to T5; Fig 1), described
here, T3 formed the baseline assessment for the evaluation of the
SDMI. After T3, women were randomly assigned to the SDMI
group or to the control group (receiving usual care). The SDMI
was added to usual care and was scheduled 2 months after the test
result. This time point was chosen so that information from the
consultations with the specialists from the Family Cancer Clinic
could be weighed into the trade-offs. These consultations usually
take place within 1 to 2 months after disclosure of a positive test
result. At T4 and T5, 3 and 9 months after the test result, a
follow-up questionnaire was sent to evaluate the short- and long-
term effects of the SDMI.
Outcome Measures
All measures were obtained at baseline (T3) and at short
(T4)- and long-term follow-up (T5), unless indicated otherwise.
Well-Being
We collected data on anxiety (state anxiety subscale of the
Spielberger State-Trait Anxiety Inventory),27 depression (Center
for Epidemiologic Studies Depression Scale),28 and intrusive and
avoidance thoughts about cancer in the family (intrusion and
avoidance subscale from the Impact of Event Scale).29 Further-
more, women were asked to rate their general health during the
last week on an 11-point scale (0, very bad; 10, excellent).
Treatment Choice
Women were asked to indicate their intended treatment
choice for the breasts and/or ovaries. When women had no breasts
or ovaries because of previous curative or prophylactic surgery,
this question was not applicable. Intended treatment choice in-
cluded prophylactic surgery, screening, and undecided. To test
differences in intended treatment choice, it was dichotomized in
prophylactic surgery versus the rest (screening and undecided).
We have combined the treatment choice screening with unde-
cided, because these women will receive the same clinical treat-
ment, namely, screening. Also, the undecided group was too small:
undecided choices decreased from 2% to 1% for the breasts, and
from 5% to 0% for the ovaries for T3 and T5, respectively. Fur-
thermore, women were asked to rate prophylactic surgery and
screening on a 10-point rating scale (1, very bad; 10, excellent) in
answering the question, “How suitable do you find prophylactic
mastectomy for yourself?” Data on the actually performed treat-
ment were also collected by questionnaire.
Decision-Related Outcomes
The decision-related outcomes were asked separately for the
breasts and ovaries. When women had no breasts or ovaries be-
cause of previous curative or prophylactic surgery, these questions
were not applicable.
Strength of treatment preference. Strength of treatment pref-
erence was asked for the treatment options prophylactic surgery
and screening on a four-point Likert scale (1, weak preference; 4,
very strong preference). Those who had chosen undecided as
treatment choice were assigned a value of zero (no preference).
Decision uncertainty. Decision uncertainty was measured
with three items related to the uncertainty subscale of the Deci-
sional Conflict Scale by O’Connor.30 Our items were “I doubt
what to choose,” “This decision is hard for me to make,” and “I am
not sure what to choose,” measured on a five-point scale (1,
strongly disagree; 5, strongly agree). A sum score was created by
averaging the items.
Perceived participation in decision making. Perceived partic-
ipation in decision making was measured with two decision-
making items from the Problem-Solving Decision-Making Scale
from Deber et al.31 The items were as follows: “Given the risks and
benefits of the possible treatment options, who has decided how
acceptable those risks and benefits are for you?” and “Who has
decided which treatment option should be selected?” These were
measured on a five-point scale (1, doctor alone; 3, doctor and I
equally; 5, I alone). A sum score was created by averaging the items.
This item had no baseline assessment.
Weighing treatment choice. Because trade-offs were promi-
nent in the SDMI, we included a single item, “I weighed the pros
and cons,” from a decision evaluation scale (Stalmeier et al, manu-
script submitted for publication). It was measured on a five-point
scale (1, strongly disagree; 5, strongly agree). This item had no
baseline assessment.
Perceived preference of the specialists. Women were asked
whether they felt that the specialists held a treatment preference
(yes/no) and, if so, its strength (strong/weak). We combined the
two answers in strong preference versus weak or no preference.
These items were only asked at T4.
Support and advice from specialists. Women were asked
whether they had wanted more support and advice from their
specialists regarding their treatment choice on a seven-point scale
(1, strongly disagree; 7, strongly agree). These items were only
asked at T4.
Sample Size and Power
We assumed that the SDMI would have a larger effect on
decision uncertainty than our informative DA.11 The SDMI is
face-to-face and more intensive, and the sample consisted of
BRCA1/2 mutation carriers who are actually facing the choice
between screening and prophylactic surgery. To detect a difference
of at least 25% in the decision uncertainty score between the two
groups with a 5% two-sided significance level and a power of 80%,
we needed a sample size of 45 women in each group.
Randomization and Blinding
Randomization of the SDMI took place by family (first-
degree up to and including third-degree relatives) to avoid con-
tamination. The randomization schedule, stratified by medical
history of breast/ovarian cancer and by timing of the informative
DA, was generated by computer in blocks of 10. Neither study
participants nor members of the study staff were blinded to inter-
vention assignment.
Statistics
Data were analyzed using the Statistical Package for the Social
Sciences (SPSS 10.0.5; SPSS Inc, Chicago, IL). We analyzed data on
an intention-to-treat basis. For missing items from multi-item
scales, we imputed the mean of the remaining items when at least
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half of the items were completed. To identify potential confound-
ing variables, we compared the SDMI and control group on base-
line characteristics using 2 tests for categoric variables and
Student’s t tests for continuous variables.
To evaluate the effects of the SDMI, we compared the SDMI
and control group on the outcome measures. For continuous
measures, comparisons were done using analyses of covariance,32
including, when present, the baseline assessment as a covariate.
Effect sizes were calculated as the adjusted mean of the SDMI
group minus the adjusted mean of the control group divided by
the SD of the difference score. When no baseline assessment was
present, effect sizes were calculated from the unadjusted mean
scores. For the two categoric variables of treatment choice and
perceived preference of the specialists, comparisons were made
using 2 tests. We used a P level of .05 to indicate statistical
significance. The number of patients providing data for the vari-
ous analyses varied because of missing data and because of nonap-
plicability of some questions.
Because randomization took place by family, and because
family members were not independent on the outcome measures,
statistical significance will be inflated when all women are treated
as independent units. The sample contained nine families with
multiple members (range, two to three members), with a total of
21 women. To counter inflation, we further examined significant
effects by incorporating only the first included family member in
the analyses.
Because previous findings showed that women affected with
breast or ovarian cancer experienced worse well-being than unaf-
fected women,33 we included cancer history in the primary anal-
yses to examine the interaction effect between the SDMI and
cancer history. Furthermore, we conducted separate analyses for
women affected and unaffected with cancer to report the various
effect sizes.
RESULTS
Participants
Figure 1 presents the study design for the whole study
(T1 to T5). At study entrance, 453 women were eligible and
390 patients (86%) gave informed consent.11 Of the women
followed up to the test result, 89 had a deleterious BRCA1/2
mutation (positive test result). Thus after the first part of
the study (T1 to T3), 89 women were eligible for the second
part of the study reported here (T3 to T5). One woman
withdrew after T3 because of high emotional distress. Of the
remaining 88 women, 44 women were randomly assigned
to the SDMI group and 44 women to the control group. In
the SDMI group, two women did not receive the SDMI, one
unaffected woman because her mother just had died of
breast cancer, and one affected woman because she had
already undergone both bilateral mastectomy and oopho-
rectomy. The follow-up at T4 was 100%. At T5, one woman
from the control group was lost to follow-up.
Baseline Characteristics
No significant differences were found between the
SDMI and control group (Table 1). The stratification for
medical history and for the allocation of timing of the
informative DA was successful.
Well-Being
In the short term (Table 2, T4), the SDMI had no effect
on any of the well-being outcomes. In the long-term (Table
2, T5), the SDMI group had less intrusive thoughts about
cancer in the family (F1,83 3.91; P .05; effect size [d]
0.30), a better general health (F1,79  6.53; P  .01; d 
0.40), and tended to be less depressed (F1,84 3.40; P .07;
d0.28). No effect was found on anxiety.
Treatment Choice
Intended treatment choice was only asked when appli-
cable. At baseline (T3), short (T4), and long term (T5), no
differences were found between the SDMI and control
group, neither on the intended treatment choice nor on the
actually performed treatment for breasts and ovaries (data
not shown). No differences were found for the ratings of the
treatment options (data not shown).
Overall, 33% (28 of 85 patients) intended to undergo
prophylactic mastectomy at T3, of whom 50% (n 14) had
undergone this treatment at T5; none of the other women
Table 1. Baseline Characteristics
SDMI (%)
(n  44)
Control (%)
(n  44)
Sociodemographics
Age, years
Mean 39.1 39.9
SD 9.7 10.4
Range
20-39 48 57
40-49 36 20
50-65 16 23
Currently married/partner 84 86
College or higher 39 34
Employed 68 73
Have children 66 77
Want (more) children 23 26
Religiously affiliated 55 70
Medical history
Personal medical history of BC/OC
No cancer 75 71
BC only 25 29
OC only 0 0
BC and OC 0 0
Family medical history of BC/OC
BC only 31 23
OC only 3 2
BC and OC 66 75
Proband 25 25
First-degree relatives with BC
or OC
68 75
First-degree relatives died of BC
or OC
52 42
Allocation of informative DA
Before test result 49 51
After test result 51 49
Abbreviations: SDMI, shared decision-making intervention; SD, standard
deviation; BC, breast cancer; OC, ovarian cancer; DA, decision aid.
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had undergone prophylactic mastectomy at T5. Overall,
68% (56 of 82 patients) intended to undergo prophylactic
oophorectomy at T3, of whom 54% (n  30) had under-
gone this treatment at T5; four of the other women had
undergone prophylactic oophorectomy at T5.
Decision-Related Outcomes
With respect to the decision-related outcomes for the
breasts, in the short term (Table 3, T4), no effects were
found. In the long term (Table 3, T5), the SDMI group held
stronger treatment preferences (F1,68  6.11; P  .02;
d 0.41) and more strongly agreed to having weighed the
pros and cons (F1,69  6.45; P  .01; d  0.42); no effects
were found for the other decision-related outcomes. With
respect to the decision-related outcomes for the ovaries, no
effects were found, neither in the short nor in the long term
(data not shown).
With respect to the behavior of the specialists, more
women in the SDMI group (29%) felt that the specialists
held a strong preference for one or the other breast treat-
ments compared with the control group (3%; 2  10.47;
P  .001). This difference was not found for the ovaries;
33% in the SDMI group, and 35% in the control group
experienced a strong preference (2  0.03; P  .87). Al-
though not significant, women in the SDMI group wanted
more support and advice from the specialists regarding
their treatment choice for the breasts (F1,78 2.94; P .09;
d  0.27); this finding was less strong for the ovaries
(F1,74 2.22; P .14; d 0.24).
Additional Analyses: Controlling for Family
Significant differences found above were further tested
by including only the first family member. Therefore, 12
persons were excluded from the analyses, seven from the
SDMI group and five from the control group. Only
the long-term effect on intrusion became insignificant
(F1,71 2.14; P .15; d 0.24).
Interaction Effects Between SDMI and
Cancer History
In the short term, no interaction effects between the
SDMI and cancer history were found for any of the well-
Table 2. Unadjusted Scores for Well-Being, Results of the ANCOVA, and Effect Sizes
Group
No. of
Patients
T3 T4
F P d
No. of
Patients
T3 T5
F P dMean SD Mean SD Mean SD Mean SD
Anxiety, STAI-state SDMI 43 39.5 12.2 35.4 11.7 0.26 .61 0.08 44 39.1 12.4 33.2 12.1 1.58 .21 0.19
Control 43 41.3 12.7 37.4 10.7 43 42.0 12.7 37.5 11.7
Depression, CESD SDMI 43 9.8 9.9 5.5 7.5 1.93 .17 0.21 44 9.6 9.9 5.8 7.4 3.40 .07 0.28
Control 43 10.5 10.4 7.5 7.3 43 10.9 10.3 9.3 10.1
Intrusion, IES SDMI 42 13.2 9.7 9.4 7.4 1.23 .27 0.17 43 12.8 9.8 8.1 8.3 3.91 .05 0.30
Control 43 12.7 9.0 10.4 7.7 43 12.8 8.8 10.9 8.5
Avoidance, IES SDMI 42 8.9 6.8 5.8 6.2 0.39 .53 0.10 43 8.7 6.9 5.7 5.9 1.42 .24 0.18
Control 43 8.0 6.4 6.0 5.7 43 8.3 6.3 6.8 6.4
General health SDMI 40 7.4 1.9 7.6 1.9 0.72 .40 0.14 42 7.5 1.9 8.1 1.4 6.53 .01 0.40
Control 38 7.5 1.7 7.9 1.3 40 7.4 1.7 7.3 1.6
Abbreviations: ANCOVA, analysis of covariance; d, effect size; STAI, State-Trait Anxiety Inventory; SDMI, shared decision-making intervention; SD, standard
deviation; CESD, Center for Epidemiologic Studies Depression Scale; IES, Impact of Event Scale.
P  .05.
Table 3. Unadjusted Scores of Decision-Related Outcomes for the Breasts, Results of the ANCOVA, and Effect Sizes
Group
No. of
Patients
T3 T4
F P d
No. of
Patients
T3 T5
F P dMean SD Mean SD Mean SD Mean SD
Strength of preference SDMI 38 2.9 0.9 3.3 0.7 0.46 .50 0.11 35 2.9 0.9 3.3 0.8 6.11 .02 0.41
Control 42 2.9 0.9 3.2 0.9 36 2.9 1.0 2.9 0.9
Decision uncertainty SDMI 38 2.3 1.0 2.1 0.9 0.58 .45 0.12 35 2.3 1.0 2.2 0.9 1.97 .17 0.23
Control 42 2.4 1.2 2.3 1.0 36 2.5 1.2 2.6 1.0
Weighing treatment choice SDMI 38 X 4.2 0.6 2.00 .16 0.22 35 X 4.3 0.5 6.45 .01 0.42
Control 41 X 4.0 0.6 36 X 3.9 0.5
Perceived participation in DM SDMI 37 X 4.1 0.6 2.72 .10 0.26 35 X 4.0 0.7 0.66 .42 0.14
Control 41 X 3.9 0.7 36 X 3.9 0.6
Abbreviations: ANCOVA, analysis of covariance; d, effect size; SD, standard deviation; SDMI, shared decision-making intervention; X, no baseline
assessment; DM, decision making.
P  .05.
van Roosmalen et al
3298 JOURNAL OF CLINICAL ONCOLOGY
131.174.209.182
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on July 13, 2012 from
Copyright © 2004 American Society of Clinical Oncology. All rights reserved.
being or decision-related outcomes. In the long term, with
respect to well-being, an interaction effect was found for
anxiety (F1,82 4.36; P  .04) and general health (F1,77 
5.71; P  .02). With respect to the decision-related out-
comes for the breasts, an interaction effect was found for
strength of preference (F1,66  3.81; P  .05), decision
uncertainty (F1,66 9.80; P .01), and participation pref-
erence (F1,67 4.64; P .04). With respect to the decision-
related outcomes for the ovaries, an interaction effect was
found for strength of preference (F1,42  12.93; P  .01)
and decision uncertainty (F1,42 17.04; P .01).
The size of the differential impact in affected versus
unaffected women is presented in Table 4. From the sepa-
rate analyses for affected and unaffected women, only effect
sizes are reported for well-being and decision-related out-
comes for the breasts. In the short term (Table 4, T4), the
SDMI had no effect on affected nor on unaffected women.
In the long term (Table 4, T5), for unaffected women,
beneficial effects were found on all outcome measures and
most were significant. The effect sizes were larger for unaf-
fected women compared with the whole group (Table 2,
Table 3, T5). For affected women, insignificant detrimental
effects were found on the above-mentioned outcomes for
which an interaction effect was found.
DISCUSSION
We evaluated an SDMI for BRCA1/2 mutation carriers who
were facing the choice between screening and prophylactic
surgery for the breasts and/or ovaries. The SDMI consisted
of trade-offs and individualized treatment information. To
our knowledge, this is the first randomized study to evaluate
such an intervention on a broad range of outcomes as a
decision support tool. Previous studies, combining value
assessment and decision analysis, have mainly concentrated
on the impact of patient preferences on treatment
choice.18-23 In the short term, 3 months after the test result,
the SDMI had no effect. In the long term, 9 months after the
test result, the SDMI group reported less intrusive thoughts
about cancer in the family, better general health, and a trend
toward less depressive thoughts. Moreover, they reported a
stronger treatment preference and more strongly agreed to
having weighed the pros and cons for the breast treatment.
It is noteworthy that two previous studies on DAs also
found stronger effects in the long term.34,35
Several types of DAs exist. The issue of what type of DA
is most effective is still unresolved.9 Our randomized study
shed some light on this issue. The informative DA had
shown beneficial effects on information-related outcomes
only,11 whereas the SDMI showed beneficial effects on a
broader range of outcomes. In a previous uncontrolled
before-after study of our group, we evaluated the informa-
tive DA and the SDMI as one package.36 Then we found
beneficial effects on information-related outcomes as well
as on more general outcomes, suggesting that the beneficial
effects of the two interventions add up. Our current study
design, with all participants receiving the initial informa-
tive DA before the randomization of the SDMI, pre-
cluded an evaluation of the interacting effects between the
informative DA and the SDMI. This might be a subject for
future research.
Nevertheless, from the present study, it is unclear
which specific element of the SDMI is effective. One possi-
ble explanation is the additional attention paid by the
research assistant. However, the time spent with the re-
search assistant was relatively short when compared with
the time spent with the specialists from the Family Cancer
Clinic. Perhaps the provision of individualized treatment
Table 4. Effect Sizes of the SDMI for Affected Versus Unaffected Women
T4 T5
Affected Unaffected Affected Unaffected
Well-being
Anxiety 0.15 0.05 0.27 0.41†
Depression 0.19 0.17 0.05 0.40†
Intrusion 0.12 0.26 0.09 0.48‡
Avoidance 0.19 0.10 0.10 0.22
General health 0.26 0.00 0.28 0.58‡
Decision-related outcomes, breasts§
Strength of preference 0.02 0.15 0.25 0.57‡
Decision uncertainty 0.19 0.23 0.61 0.56‡
Weighing treatment choice 0.13 0.27 0.12 0.59‡
Perceived participation in DM 0.37 0.19 0.52 0.32
Abbreviations: SDMI, shared decision-making intervention; DM, decision making.
Number of patients per group varied from 10 to 12 for affected and from 29 to 33 for unaffected women.
†P  .05.
‡P  .01.
§Number of patients per group varied from five to 11 for affected and from 27 to 31 for unaffected women.
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information is effective. However, as our informative DA
had only beneficial effects on information-related outcomes
and none whatsoever on well-being and decision-related out-
comes,11 this seems unlikely. Another explanation, which
needs to be followed up in future work, is that during decision
support, negative emotions are expressed more strongly.37
This is known to enhance well-being over the long term.38
On the basis of our own data, we hypothesize that the
trade-offs are the effective component of the SDMI. These
trade-offs explicitly required women to consider their val-
ues in the light of quality and length of life. The effect of the
trade-offs is evident as women in the SDMI group more
strongly agreed to having weighed the pros and cons, sug-
gesting a more deliberated treatment choice. This might
lead to stronger treatment preferences in women from the
SDMI group, as indeed we found. Furthermore, as these
women explored their own preferences, they might more eas-
ily discern their own preferences from the preferences of
the specialists, as indeed we found. Our hypothesis is further
supported by psychologic work showing that contrasting the
future with reflections on present reality (the trade-offs have
that effect) strengthens goal commitments, which may lead to
improved well-being.39 If indeed the beneficial effects could be
attributed to the trade-offs, decision making might be im-
proved by actively exploring individual values for the treat-
ment options in a systematic way using trade-offs.
Next to establishing the essential elements of a DA,
there is also a need to identify the people who are most likely
to benefit.9 In the long term, we found various interaction
effects between the SDMI and cancer history. Subgroup
analyses revealed that the SDMI had an overall beneficial
effect for unaffected women and detrimental effects for
affected women, although the SDMI was evaluated equally
by affected and unaffected women (data not shown). Sev-
eral explanations may apply. First, affected women may
have received individualized treatment information that
was discordant with their treatment intention more often.
However, the opposite was found: treatment intentions and
the best option based on QALE agreed in 70% of the af-
fected women and in 44% of the unaffected women. Sec-
ond, affected women (45 years) were older then unaffected
women (37 years), and it may be that the SDMI is less
effective in older women. However, in the unaffected sam-
ple, the beneficial effects of the SDMI were independent of
age. Furthermore, affected and unaffected women did not
differ at baseline (T3) on other potential explanatory vari-
ables such as risk perception and preference for decision
making (data not shown). So it remains unclear why the
SDMI is not effective in affected women. Previously, we
found that affected women tended to react more strongly
toward a positive DNA test result.33 Perhaps the additional
confrontation with trade-offs is simply too taxing for af-
fected women, in view of the burden of being at risk for a
second cancer. Further studies are needed with larger sam-
ple sizes to confirm these effects.
In general, DAs are meant to supplement, not replace,
the traditional process of patient counseling by clinicians.
Can the present SDMI be implemented into a Family Can-
cer Clinic? The present study shows it is feasible to imple-
ment such an intervention in the clinic within a research
context. Our study reveals that the SDMI is acceptable to
women; further study is needed about the acceptability to
counselors. However, the TTO interview is labor-intensive,
requiring on average of 1 hour per patient when performed
face-to-face and 30 minutes when repeated by telephone.
The time needed to perform the decision analysis, including
sensitivity analyses, depends on the cancer history. For af-
fected women, the prognosis needs to be determined and
included in the decision analysis, which may take some
hours. For unaffected women, the decision analysis takes
half an hour. Furthermore, performing TTO interviews,
conducting individual decision analyses, and sharing treat-
ment information requires well-trained personnel. Of
course, the SDMI is not complete without using the infor-
mative DA.11 This information material and the decision
model need to be kept up-to-date. Time pressure and costs
of implementing decision aids are frequently cited as barri-
ers for using decision aids.40 Despite these barriers, we
believe that a simplified version of the SDMI, perhaps in-
volving only the trade-offs, can be integrated into a consul-
tation with a social worker or genetic counselor. This may
not require much extra time per patient, as the trade-offs
could be used as a basis for further deliberations.
It is acknowledged that some of the significant differ-
ences observed in this study could be due to chance, given
the number of statistical tests. However, for unaffected
women, all measures consistently pointed in a beneficial
direction. Furthermore, the sample size is relatively small.
Other limitations are that we know nothing about its cost
effectiveness and how the counselors view the SDMI.
We conclude that the SDMI improved decision mak-
ing in unaffected BRCA1/2 mutation carriers. Our advice
is to support decision making in these women in a sys-
tematic way using trade-offs. The SDMI is not recom-
mended for affected women. Future research should
concentrate on how and for whom this intervention
could be implemented profitably in the clinical practice
of Family Cancer Clinics.
  
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